Diabetes Mellitus, Type 2
Conditions
Brief summary
The study is intended to estimate the proportion and clinical management of people with type 2 diabetes having atherosclerotic cardiovascular diseases or who are at high risk to develop atherosclerotic cardiovascular diseases. Participants will be asked to give information about their health. Partipants will continue normal way of life and will not get any medication other than those prescribed to them by the doctor. The study will last for about 6 months.
Interventions
OTHERNo treatment given
The clinical management and prescribed treatment of diabetes and eASCVD/ASCVD risk factors are independent of this study and are part of the routine clinical practice at the discretion of the treating physician.
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. Male or female, age greater than or equal to 18 years at the time of signing informed consent. 3. Diagnosed with T2D grater than or equal to 180 days prior to the day of signing informed consent
Exclusion criteria
1. Previous participation in this study. Participation is defined as having given informed consent in this study. 2. Mental incapacity, unwillingness, inability, or language barriers precluding adequate understanding or cooperation 3. Diagnosed with Type 1 Diabetes (T1D). 4. Patients with known congenital heart disease/malformation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with Established Atherosclerotic Cardiovascular Disease (eASCVD) pooled across all countries and separately for each country in scope | At the time of patient enrolment (Day 1) | Percentage patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of T2D patients with high risk of Atherosclerotic cardiovascular disease (ASCVD) and without eASCVD | At the time of patient enrolment (Day 1) | Percentage patients |
Countries
Bahrain, Egypt, Jordan, Kuwait, Qatar, South Africa, United Arab Emirates
Outcome results
None listed